Sort
10,766 grants matching “checkpoint inhibitor”
Role of MetAP-2 in Angiogenesis and Wnt Signaling
$460,628Craig M Crews · Yale University · R01 · FY2010 · CA
The Effects of Prior Checkpoint Inhibitor (CPI) Therapy on Mouse Hepatitis Coronavirus Induced Pneumonia
$460,497Parizad Torabi-Parizi · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL
Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion
$460,485Beth A Weaver · University Of Wisconsin-Madison · R01 · FY2023 · CA
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs
$460,426Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2020 · CA
Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients
$460,204Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients
$460,204Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer
$460,148Nupam P Mahajan · Washington University · R01 · FY2024 · CA
Lung Resident Mesenchymal Cells in the Pre-Metastatic Niche Formation
$460,093Guangwen Ren · Jackson Laboratory · R01 · FY2024 · CA
DNA Methylation Inhibitor Therapy for Testicular Cancer
$459,898Michael J Spinella · University Of Illinois At Urbana-Champaign · R01 · FY2019 · CA
Informatics strategies to improve immune-related adverse event detection in cancer patients
$459,867Danielle S Bitterman · Brigham And Women'S Hospital · R01 · FY2024 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
$459,865Eric T Ahrens · University Of California, San Diego · R01 · FY2021 · CA
Duke-UNC Chapel Hill Immunotherapy Training Grant
$459,827Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · T32 · FY2021 · CA
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
$459,017Wei Gu · Columbia University Health Sciences · R01 · FY2023 · CA
Project 2: Deciphering the Dynamic Evolution of the Tumor-Immune Interface
$459,005Forest M White · Massachusetts Institute Of Technology · U54 · FY2023 · CA
Dissecting the NRG4 hormonal checkpoint in metabolic liver disease
$458,998Jiandie D Lin · University Of Michigan At Ann Arbor · R01 · FY2024 · DK
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer
$458,906Terence Marques Williams · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment
$458,847E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2024 · NS
Cancer Immunotherapy Clinical Trials
$458,587Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Targeting apoptotic caspases to enhance cancer radiotherapy
$458,400Fang Li · Duke University · R01 · FY2022 · CA
Intrapleural immunotherapeutic nanoparticles for MPE treatment
$458,346Dawen Zhao · Wake Forest University Health Sciences · R01 · FY2025 · CA
An innate immune checkpoint in cancer immunotherapy
$458,186Carla Rothlin · Yale University · R01 · FY2021 · CA
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
$458,029Alice Berger · Fred Hutchinson Cancer Center · R37 · FY2023 · CA
02 - Experimental Therapeutics
$457,959Suzanne Elizabeth Lapi · University Of Alabama At Birmingham · P30 · FY2025 · CA
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.
$457,838Maria G Castro · University Of Michigan At Ann Arbor · R01 · FY2025 · NS
Targeting PP4 to improve ovarian cancer response to immunotherapy
$457,776Marion Curtis · Mayo Clinic Arizona · R37 · FY2025 · CA